Further, only sorafenib was able to elevate SHP-1 phosphatase activity and induce effective apoptosis in HCC cells, in comparison with brivanib and sunitinib, suggesting that p-PKM2Y105 downregulation may determine the sensitivity of these targeted drugs via SHP-1 activation (Figure 4B and 4C). This evidence concerns the gene PTPN6 and hepatocellular carcinoma.